

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 476 233 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
14.02.1996 Bulletin 1996/07

(51) Int Cl.⁶: **C12N 15/18, A61K 38/27,
C07K 14/475**

(21) Application number: **91108943.1**

(22) Date of filing: **31.05.1991**

(54) **Human MK gene and protein sequence**

Menschliches MK Gen und Protein-Sequenz

Gène MK humain et séquence de la protéine

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: **20.08.1990 US 568573**
02.05.1991 US 650795

(43) Date of publication of application:
25.03.1992 Bulletin 1992/13

(73) Proprietor: **AMERICAN CYANAMID COMPANY**
Wayne, NJ 07470-8426 (US)

(72) Inventors:
• **Kovesdi, Imre**
Pearl River, New York 10965 (US)
• **Bohlen, Peter**
Peekskill, New York 10566 (US)

(74) Representative:
Wächtershäuser, Günter, Prof. Dr.
D-80331 München (DE)

(56) References cited:
EP-A- 0 326 075

- **BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS** vol. 176, no. 2, 30 April 1991, pages 792-797, New York, US; J.-I. TSUTSUI et al.: "A New Family of Heparin-Binding Factors: Strong Conservation of Midkine (MK) Sequences between the Human and the Mouse "
- **BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS** vol. 171, no. 2, 14 September 1990, pages 603-609, New York, US; M. TOMOMURA et al.:
- **THE JOURNAL OF BIOLOGICAL CHEMISTRY** vol. 265, no. 18, 25 June 1990, pages 10765-10770, Baltimore, US; M. TOMOMURA et al.: "A Retinoic Acid- responsive Gene, MK, Found in the Teratocarcinoma System"
- **THE JOURNAL OF BIOLOGICAL CHEMISTRY** vol. 265, no. 16, 5 June 1990, pages 9441-9443, Baltimore, US; S. MATSUBARA et al.: "Structure of a Retinoic Acid-responsive Gene, MK, Which is Transiently Activated During the Differentiation of Embryonal Carcinoma Cells and the Mid-gestation Period of Mouse Embryogenesis"
- **BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS** vol. 151, no. 3, 30 March 1988, pages 1312-1318, New York, US; K. KADOMATSU et al.: "cDNA cloning and Sequencing of a New Gene Intensely Expressed in Early Differentiation Stages of Embryonal Carcinoma Cells and in Mid-Gestation Period of Mouse Embryogenesis"

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

This invention relates to a novel DNA sequence for a protein having substantial homology to human heparin binding neurotrophic factor (HBNF). The sequences in question also show a high degree of homology with a previously described murine protein designated as MK1. The homology of MK with these known proteins suggests a similar utility in induction of nerve cell growth and differentiation, as well as nerve cell maintenance and repair. Moreover, the occurrence of the MK gene in teratocarcinoma cells and embryonic development indicates broader utility as a differentiation inducing factor, as well as a tissue maintenance or repair factor.

The protein of the present invention is normally produced in the human brain, but apparently at a different time, developmentally, than HBNF. The human MK protein shows about an 85% homology with the published mouse MK sequence. No recognition of the existence of such a protein in humans has previously been made, although it now appears that MK is a member of a highly conserved gene family which is present in a number of different species.

The gene encoding the human MK protein has been isolated from a cDNA library obtained from human newborn brain stem RNA. The gene has been sequenced and cloned; it is a 366-nucleotide sequence predicting a protein having 121 amino acids.

BACKGROUND OF THE INVENTION

Kadomatsu *et al.* (Biochem. Biophys. Res. Comm. 151:1312-1318, 1988) isolated and sequenced cDNA from mouse cells, which they referred to as MK1. The corresponding mRNA was said to be abundant in the early stages of mouse embryonic development, but not in later stages. The MK1 protein was suggested as being associated with control of cell differentiation, specifically as a DNA binding protein regulating gene expression. No relationship to any other known protein sequences was found. A subsequent paper (Tomomura *et al.*, J. Biol. Chem. 265:10765-10770, 1990) reported the expression of the MK gene in early stages of embryonal carcinoma cell differentiation, and also noted the occurrence of three distinct classes of cDNA clones, referred to as MK1, MK2 and MK3. Kadomatsu *et al.* (J. Cell. Biol. 110:607-616, 1990) suggested MK may play a fundamental role in the differentiation of a variety of cells, and that it may be involved in the generation of epithelial tissues and in the remodeling of mesoderm.

The mouse MK1 sequence has now been found to have a high degree of homology in the group of proteins known as heparin-binding neurotrophic factors (HBNFs); the nucleotide sequence encoding the latter proteins has been disclosed in applicants' copending and cofiled Serial No. 07/568,574. The HBNF proteins were originally disclosed as HBBMS, in EP 325076. It has now been unexpectedly discovered that a gene corresponding to the mouse MK sequence is also found in human brain. The present invention provides the entire sequence of the gene encoding the human protein, as well as the predicted amino acid sequence of the mature protein, cloning and expression vectors, and host cells capable of expressing the gene and producing pure MK protein. In view of the strong homology between the MK proteins and HBNF, it is likely that these constitute a family of genes and proteins having developmental significance.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 (See also Sequence Listing 1). Nucleotide and amino acid sequence of the human MK gene. Boldfaced amino acids represent the predicted protein presequence, the arrow represents the predicted N-terminus of the mature protein, and the two peptide sequences corresponding to primers 1 and 2 used to amplify the mouse genomic DNA probe are underlined. The two polyadenylation sequences near the 3' end of the gene are underlined.

Figure 2 shows a comparison of the mature protein region of human HBNF (See also Sequence Listing 3) and MK nucleotide and deduced amino acid sequence. Identical amino acids are indicated in bold letters. Identities in the two nucleotide sequences are indicated by stars (*).

Figure 3 shows a nucleotide sequence and deduced amino acid sequence of human and mouse MK (See also Sequence Listing 2). Differences in the two nucleotide sequences are indicated by stars (*). Differences in the amino acids are indicated in bold letters. Amino acids used in the mouse genomic PCR primer design are underlined.

Figure 4. Bacterial Expression of human recombinant HBNF and MK proteins. Cell lysates are from bacterial cultures containing the expression plasmids pETHH8 or pETMH2. Lanes 1 and 2, lysates from uninduced and IPTG-induced cultures containing pETMH2. Lane 3, purified recombinant MK protein. Lanes 4 and 5, uninduced and induced cultures containing pETHH8. Lane 6, purified recombinant HBNF protein. Protein standards are from BRL.

Figure 5. Neurite outgrowth assays of purified recombinant HBNF and MK proteins. Purified proteins are assayed on 18-day fetal rat neurons at concentrations indicated. (A) Neuronal cells with no added protein. (b) Bovine brain-derived HBNF protein (160 ng/ml). (C) Purified recombinant human HBNF protein (150 ng/ml). (d) Purified recombinant human MK protein (150 ng/ml).

Figure 6 shows (a) Expression of HBNF gene during rat embryogenesis. From each tissue 20 ug total RNA was applied per lane and hybridized with a ³²P-labeled human HBNF cDNA probe. Tissues used in the RNA isolation were

total embryo proper for E8 and E10, heads for E12 and E14, total brain for E16, E18, E20, P2 and Adult; (b) expression of MK gene during rat embryogenesis. Same northern blot as in (a) hybridized with a ^{32}P -labeled human MK cDNA probe.

Figure 7. Gene expression of HBNF and MK in the adult rat brain. RNA extracted from various brain regions of 2-month-old rats was subjected to northern analysis (10 μg /lane of RNA; Lane 1 - total brain, 2 - cortex, 3 - hippocampus, 4 - cerebellum, 5 - caudate nucleus, 6 - midbrain + hypothalamus, 7 - brain stem). The resulting blot was hybridised consecutively to probes for HBNF, MK and β -actin.

Figure 8. Retinoic acid-induced expression of HBNF and MK genes in NT2/D1 cells. NT2/D1 cells were treated with varying concentrations of RA, grown for 9 days, and RNA extracted. (A) For each RA concentration of 10 μg of RNA was used in northern analysis. The resulting blot was consecutively hybridized with HBNF, MK and β -actin probes. (B) Hybridization signals obtained in (A) for HBNF (black) and MK (hatched) were measured by densitometry and normalised to the β -actin signals.

DETAILED DESCRIPTION OF THE INVENTION

The DNA sequence encoding human MK is cloned by isolating a combination of polymerase chain reaction (PCR) and screening of a cDNA library derived from newborn human brain stem. The human HBNF sequence is used as the starting point for designing oligonucleotides for a PCR amplification reaction; this sequence is shown in Figure 2. Specific oligonucleotides are designed to the regions most conserved between HBNF and the published mouse MK1 DNA sequence. These oligonucleotides are used as primers in a polymerase chain reaction (PCR) on mouse genomic DNA. The expected 150 base pair product is cloned in an appropriate vector and the sequence determined. This clone is used as a probe for screening a human brain cDNA library to identify the human MK equivalent gene. A single clone is isolated, subcloned and sequenced. The sequence of one of these clones is shown in Figure 1, and accounts for 790 nucleotides of the estimated 1100 nucleotides of mature human MK mRNA. The nucleotide sequence is subsequently confined in additional shorter-length MK clones, which are found to contain different overlapping fragments of the original clone. The sequence of the MK cDNA includes two polyadenylation signals and a poly A tail (Figure 1). The original isolated clone has an open reading frame with a coding region beginning at nucleotide 22 and defining a 143 residue protein. The N-terminal sequence is highly hydrophobic and has the characteristics of a signal peptide (Von Heijne, J. Mol. Biol. 184:99-105, 1985). On the basis of the criteria for signal peptide structures set forth by Von Heijne (*id.* Nucl. Acid Res. 14:4683-4690, 1986) and comparisons with mouse MK and human HBNF sequences, it is assumed that signal peptide cleavage occurs between amino acid residues 22 (Ala) and 23 (Lys), thus giving rise to a mature MK polypeptide of 121 residues in length.

As shown in Figure 3, a comparison of the human MK deduced amino acid sequence with the mouse MK protein sequence indicates a difference of only about 15%. Most of these changes are conservative. The homology between MK and HBNF, shown in Figure 2, indicates a homology of 50%, increasing to 63% when conserved amino acid changes are included. Ten Cysteines which are present in both proteins are perfectly aligned, suggesting similar structures.

To provide a source of the mature MK protein free of contaminating eukaryotic proteins, cDNA clones isolated above are used as templates for PCR amplification with primers designed to place a methionine codon immediately 5' of the N-terminal lysine residue of the mature proteins. The amplified product is cloned into a modified form of the expression vector pET-3a (Studier, *et al.*, 1990), and the resulting plasmid pETMH2 is transformed into *E. coli* strain BL21 *LysS*. Protein extracts of IPTG-induced pETMH2-containing bacteria express a major protein band migrating at approximately 16.5 kDa (Figure 4, Lane 2). Uninduced culture (Lane 1, pETMH2-containing bacteria) contains much less of the protein as judged by SDS-PAGE band intensities. Recombinant MK protein is purified from IPTG-induced bacterial cultures by heparin affinity chromatography (Figure 4, Lane 3) and its N-terminal sequence and amino acid compositions confirmed.

Homology between the human and published mouse MK DNA and the deduced protein sequences show a lower level of conservation than a similar evolutionary comparison of HBNF (Figure 3). Using a putative N-terminus from the mature MK protein deduced from homology with HBNF, 86% amino acid identity is observed including a three amino acid deletion in the mouse sequence. Both HBNF and MK are expressed in brain but their temporal and spatial regulation differs. Preliminary *in situ* hybridisation showed distinct patterns of expression for the two messages. Northern hybridization analysis of mouse RNA from the adult tissues examined indicates that only brain expressed a 1650-nucleotide HBNF message (Figure 6). This is consistent with previous investigations on the expression characteristics of the HBNF protein which show it is present in the brain (EP 326 075, Rauvala, EMBO J. 8:2933-2941, 1989). Recently, HBNF protein was also isolated from bovine uterus (Milner *et al.* Biochem. Biophys. Res. Comm. 165:1096-1103, 1989). These initial experiments indicated that MK is not expressed in any adult tissue examined (Figure 6). However, subsequent experiments indicate that MK mRNA is detectable in two regions of the adult brain, the caudate nucleus and the brain stem (Figure 7). Based on the significantly longer exposure times needed to see these bands in adult RNA as compared to equivalent amounts of embryonic RNA, it appears that MK RNA is expressed at minimal levels in the adult.

The temporal expression of both genes is evaluated by northern blot analysis with total rat RNA from various developmental stages. Hybridization with an HBNF probe indicates a gradual increase of message throughout develop-

ment, with the highest level occurring in the adult brain (Figure 6a). Hybridization of the same blot with an MK probe indicates that only 12-, 14- and 16-day embryonic tissues contained the message. The most abundant presence of MK message appears to be in the embryonic day 12 stage (Figure 6b). These results are in general agreement with the in situ hybridisation studies of Kadomatsu (supra). However, contrary to the findings of Kadomatsu, we were unable to detect MK mRNA expression in kidney tissue. Studies of HBNF protein in rat brains suggest that the highest level occurs in postnatal day-7 pups. This level reflects a ten-fold difference when compared to 56-day old animals (Rauvala, supra).

The human embryonal carcinoma (EC) cell line NT2/D1 can be induced to differentiate at concentrations of retinoic acid (RA) varying from 0.01 to 10 μ M, with the proportion of differentiating EC cells ranging from 50% at 0.01 μ M RA (Simeone, et al., Nature 346:763-766, 1990) to greater than 99% at 1 and 10 μ M RA (Andrews, Dev. Biol. 103:285-293, 1984). The expression of MK and HBNF during differentiation of NT2/D1 is studied, at concentrations ranging from 0.01 to 10 μ M. After nine days of exposure to RA, total RNA was extracted from cells and probed for gene expression by northern analysis. Expression of both genes followed a similar pattern (Figure 8). Levels of mRNA expression remained at a steady background level with 0.1-0.5 μ M RA, rapidly increased between 0.1 and 0.5 μ M RA, and maintained this level at concentrations up to and including 10 μ M RA. When RNA hybridization signals were normalized to a control β -actin probe, the maximum increases were calculated to be 6-fold for HBNF and 11-fold for MK (Figure 8). These results are comparable to those observed for MK during retinoic acid induction of the mouse EC cell line, HM-1 (Kadomatsu et al., supra). In this cell line, MK gene expression was induced 8-10 fold above background.

Recombinant HBNF and MK proteins are assayed for the ability to stimulate neurite outgrowth of 18-day fetal rat brain neurons. Both bacterially-derived proteins showed neurite outgrowth-promoting activity similar to that of native bovine HBNF (Figure 5). The recombinant MK protein is also assayed for mitogenic activity on adult bovine aortic endothelial cells and NIH 3T3 fibroblasts. MK protein shows no mitogenic activity on these cells. However, conditioned medium from MK-transfected L cells has been reported to be mitogenic from PC12 cells by Tomomura (Biochem. Biophys. Res. Comm. 171: 603, 609, 1990).

The findings of the present invention thus indicate that HBNF and MK are members of a highly conserved gene family. Furthermore, the gene expression data implies that these genes function in the proliferation, maintenance and/or developmental differentiation of tissue and, in particular, nerve tissue.

The following examples illustrate the cloning and expression of the MK gene in a T7 RNA polymerase expression system. However, although this T7 expression system is quite efficient, it is to be understood that this is not the only means by which MK can be produced recombinantly. Production of MK can be achieved by incorporation of the MK gene into any suitable expression vector and subsequent transformation of an appropriate host cell with the vector; alternately the transformation of the host cells can be achieved directly by naked DNA without the use of a vector. Production of MK by either eukaryotic cells or prokaryotic cells is contemplated by the present invention. Examples of suitable eukaryotic cells include mammalian cells, plant cells, yeast cells and insect cells. Similarly, suitable prokaryotic hosts, in addition to E. Coli, include Bacillus subtilis.

Other suitable expression vectors may also be employed and are selected based upon the choice of host cell. For example, numerous vectors suitable for use in transforming bacterial cells are well known. For example, plasmids and bacteriophages, such as λ phage, are the most commonly used vectors for bacterial hosts, and for E. Coli in particular. In both mammalian and insect cells, virus vectors are frequently used to obtain expression of exogenous DNA. In particular mammalian cells are commonly transformed with SV40 or polyoma virus; and insect cells in culture may be transformed with baculovirus expression vectors. Yeast vector systems include yeast centromere plasmids, yeast episomal plasmids and yeast integrating plasmids.

It will also be understood that the practice of the invention is not limited to the use of the exact sequence of the MK gene as defined in Figure 1. Modifications to the sequence, such as deletions, insertions, or substitutions in the sequence which product silent changes in the resulting protein molecule are also contemplated. For example, alterations in the gene sequence which result in the production of a chemically equivalent amino acid at a given site are contemplated; thus, a codon for the amino acid alanine, a hydrophobic amino acid, can readily be substituted by a codon encoding another hydrophobic residue, such as glycine, or may be substituted with a more hydrophobic residue such a valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule frequently do not alter protein activity, as these regions are usually not involved in biological activity. It may also be desirable to eliminate one or more of the cysteines present in the sequence, as the presence of cysteines may result in the undesirable formation of multimers when the protein is produced recombinantly, thereby complicating the purification and crystallization processes. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Therefore, where the phrase "MK DNA sequence" or "MK gene" is used in either the specification or the claims, it will be understood to encompass all such modifications and variations which result in the production of a biologically equivalent MK protein. In particular, the invention contemplates those DNA sequences which are sufficiently duplicative of the sequence of

Figure 1 so as to permit hybridisation therewith under standard high stringency southern hybridisation conditions, such as those described in Maniatis *et al.*, (Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, 1982). The MK protein is strongly homologous to the HBNF protein and, like HBNF, stimulates induction of neurite outgrowth. MK is, therefore, proposed as a neurotrophic agent. As such, the MK proteins are useful both *in vivo* and *in vivo*, in growth, maintenance and repair of nerve cells of the peripheral and central nervous systems. An example of *in vitro* application is in maintenance of embryonic brain implants which are now proposed for use in treatment of Parkinson's disease.

In view of the apparent role in differentiation, the MK protein is also proposed as a general tissue differentiation, maintenance and repair factor. In particular, MK may be useful in treatment of tumor cells to induce reversion to a differentiated phenotype.

In vivo administration of MK is significantly simplified by the discovery of the gene sequence, particularly in treatment of central or peripheral nervous system injury. The identification of the gene and its sequence permit construction of transgenic cells such as fibroblasts, monocytes, or macrophages, which may be engineered to permit expression of the MK gene and used as an implant for treatment of neurodegenerative disorders, peripheral nerve repair following surgery, or any conditions in which enhancement of nerve cell growth and/or repair would be desirable.

Moreover, the therapeutic use of MK is not limited to treatment of humans alone. In fact, in view of the conserved nature of this protein among distantly related species, administration of MK in any form may be beneficial for veterinary application as well. Therapeutic compositions comprise MK in an amount effective to induce the desired biological activity in combination with a pharmaceutically acceptable liquid or solid carrier. Alternately, the composition comprises a pharmaceutically acceptable aggregation of compatible transgenic cells capable of expressing MK *in vitro*, as an implant for peripheral and central nervous system repairs or differentiation treatment.

EXAMPLE

CLONING AND SEQUENCING OF THE MK GENE

The published mouse MK protein amino acid sequence was used to create specific oligonucleotides to be used as primers in a polymerase chain reaction. Mouse genomic DNA was isolated from C57 Black/6J mice, as described in Maniatis *et al. supra*.

A sense primer is made to the amino acid sequence: CNWKKEFG (Figure 1) starting with a HindIII restriction site and comprised of the DNA sequence:

5' GGAATTCGGTCTCCTGGCACTGGGCAGT-3'.

The PCR reaction is carried out on the complementary DNA template with a minute annealing at 50°C, 2 minutes extension at 72°C and 1 minute denaturation at 94°C for 30 cycles using Tag polymerase (USB Corp.)

The 150 base pair mouse MK PCR product is cloned into Blue Scribe (+) vector (Stratagene) and used as a probe in screening a newborn brain stem and basal ganglia λ gt 11 cDNA library (Kamholz, PNAS USA 83:4962-54966, 1986). A single putative clone containing the MK sequence is isolated and subcloned into the EcoRI site of Blue Scribe (+) and sequenced by the dideoxynucleotide chain termination method (Sanger *et al.* PNAS USA 74:5463-5467, 1988) The sequence of the MK gene, as well as the predicted amino acid sequence is presented in Figure 1. Comparison with the mouse MK sequence shows a 41 nucleotide difference, including the three codon deletion in the mouse sequence.

EXPRESSION OF RECOMBINANT HUMAN MK

The isolated clone noted above, referred to as pMKHC2 is used as a template for PCR amplification with primers designed to place a methionine codon and an Nde I restriction site immediately 5' to the N-terminal lysine. The purified PCR product is cloned into a derivative of the expression vector pET-3a, which is modified by the deletion of the 1400 bp Sall/PvuII fragment and insertion of an f1 origin of replication into the EcoRI site. After sequencing the insert to confirm the fidelity of the PCR amplification, the plasmid (named pETMH2; also previously referred to as pETMKHC2) is transformed into strain BL21 lysS and induced for protein production with IPTG as described (Studier *et al. supra*). Pellets from one ml culture are resuspended in 100 μ l of SDS buffer (Laemmli, Nature 227:680-685, 1970) and 2.5 μ l run on a 15 acrylamide SDS-PAGE gel. The gel is stained with coomassie blue. Recombinant MK is purified from bacterial extract on heparin sepharose CL-6B (Pharmacia) resin in 10 mM Tris, pH 7.0 and eluted at 1-1.13 M NaCl. Further purification is achieved on Mono S (Pharmacia) columns in 50 mM sodium phosphate, pH 6.8, with increasing salt concentration from 0 to 1 M NaCl. Purified protein is eluted at .6 M NaCl.

NEURITE OUTGROWTH ASSAYS

Brains from 18-day fetal rats are removed under sterile conditions and dispersed to single cells in DMEM containing 10% FCS using a sterile 5 ml syringe. The cell suspension is adjusted to 5×10^5 cells/ml and plated onto tissue culture dishes that are precoated with 50 μ g/ml poly-L-lysine for 30 minutes at room temperature (Rauvala and Pihlaskari, J. Biol. Chem. 262:16625-16635, 1987). Cultures are incubated for 24 hours at 37°C in 10% CO₂, after which the media is changed to DMEM containing 1 mg/ml BSA, and HBNF or MK proteins are added at indicated concentrations. After a further one-day incubation, neurite outgrowth activity is determined by visual examination of cells for extended outgrowth/processes as compared to controls. As shown in Figure 5D, purified recombinant MK is capable of stimulating neurite outgrowth to substantially the same extent as recombinant HBNF and bovine brain derived HBNF.

GROWTH AND RETINOIC ACID INDUCTION OF THE HUMAN NT2/D1 CELLS

The human embryonal carcinoma cell line NT2/D1 is grown as described previously (Andrews, Dev. Biol. 103:285-293, 1984). For retinoic acid induction, cells are grown and resuspended in DMEM medium containing 10% bovine calf serum and resuspended in DMEM medium containing 10% bovine calf serum (Hyclone Laboratories, Inc.) at a density of 5×10^5 cells per 100 mm dish. Varying concentrations of all-trans retinoic acid in dimethyl sulfoxide (10 μ l) is added, and cells are incubated for 9 days. Fresh medium and RA are added at days 4 and 8. Plates are washed once with phosphate buffered saline, and RNA extracted as described above. Figure 8 shows a graphic representation of the levels of both HBNF and MK produced in response to varying levels of retinoic acid concentration. Since NT2/D1 cells induced with RA have been suggested as providing a model system for studies of neuronal differentiation (Lee and Andrews, J. Neurosci. 6:514-521, 1986), the increase in induction of HBNF and MK genes in this system indicates a possible role in neuronal cell development.

DEPOSIT OF BIOLOGICAL MATERIALS

E. coli strain M 1061 harboring pMKHC2 and E. coli strain BL2T LysS harboring pETMH2 have been deposited in the culture collections of American cyanamid Company, Lederle Laboratories, Pearl River, New York, and with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, under accession number ATCC 68384, on August 13, 1990 and accession number 68401, on September 17, 1990, respectively.

Sequence ID No.: 1

Sequence Type: Nucleic Acid and Amino Acid

Sequence Length: 799 Base Pairs 143 Amino Acids

Strandedness: Single

Topology: Linear

Original Source Organism: Human

Properties: Human MK Gene and Protein Sequence

	CGGGCGAAGC AGCGCGGGCA GCGAG	25
20	ATG CAG CAC CGA GGC TTC CTC CTC CTC ACC CTC CTC Met Gln His Arg Gly Phe Leu Leu Leu Thr Leu Leu 1 5 10	61
25	GCC CTG CTG GCG CTC ACC TCC GCG GTC GCC AAA AAG Ala Leu Leu Ala Leu Thr Ser Ala Val Ala Lys Lys 15 20	97
30	AAA GAT AAG GTG AAG AAG GGC GGC CCG GGG AGC GAG Lys Asp Lys Val Lys Lys Gly Gly Pro Gly Ser Glu 25 30 35	133
35	TGC CGT GAG TGG GCC TGG GGG CCC TGC ACC CCC AGC Cys Ala Glu Trp Ala Trp Gly Pro Cys Thr Pro Ser 40 45	169
40	AGC AAG GAT TGC GGC GTG GGT TTC CGC GAG GGC ACC Ser Lys Asp Cys Gly Val Gly Phe Arg Glu Gly Thr 50 55 60	205
45	TGC GGG GCC CAG ACC CAG CGC ATC CGG TGC AGG GTG Cys Gly Ala Gln Thr Gln Arg Ile Arg Cys Arg Val 65 70	241
50	CCC TGC AAC TGG AAG AAG GAG TTT GGA GCC GAC TGC Pro Cys Asn Trp Lys Lys Glu Phe Gly Ala Asp Cys 75 80	277
55	AAG TAC AAG TTT GAG AAC TGG GGT GCG TGT GAT GGG Lys Tyr Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly 85 90 95	313
55	GGC ACA GGC ACC AAA GTC CGC CAA GGC ACC CTG AAG Gly Thr Gly Thr Lys Val Arg Gln Gly Thr Leu Lys 100 105	349

5	AAG GCG CGC TAC AAT GCT CAG TGC CAG GAG ACC ATC Lys Ala Arg Tyr Asn Ala Gln Cys Gln Gly Thr Ile 110 115 120	385
10	CGC GTC ACC AAG CCC TGC ACC CCC AAG ACC AAA GCA Arg Val Thr Lys Pro Cys Thr Pro Lys Thr Lys Ala 125 130	421
15	AAG GCC AAA GCC AAG AAA GGG AAG GGA AAG GAC TAG Lys Ala Lys Ala Lys Lys Gly Lys Gly Lys Asp Xaa 135 140	457
20	ACGCCAAGCC TGGATGCCAA GGAGCCCCTG GTGTCACATG GGGCCTGGCC ACGCCCTCCC TCTCCCAGGC CCGAGATGTG ACCCACCAGT GCCTTCTGTC TGCTCGTTAG CTTTAATCAA TCATGCCCTG CCTTGTCCCT CTCACTCCCC AGCCCCACCC CTAAGTGCCC AAAGTGGGGA GGGACAAGGG ATTCTGGGAA GCTTGAGCCT CCCCCAAGC AATGTGAGTC CCAGAGCCCG CTTTTGTCT TCCCCACAAT TCCATTACTA AGAAACACAT CAAATAAACT GACTTTTCC CCCCAATAAA AGCTCTTCTT TTTTAATATA AAAAAAAAAA AA	497 537 577 617 657 697 737 777
30		799
35		
40		
45		
50		
55		

Sequence ID No.: 2

Sequence Type: Nucleic Acid and Amino Acid

Sequence Length: 354 Base Pairs 118 Amino Acids

Strandedness: Single

Topology: Linear

Original Source Organism: Mouse

Properties: Mouse MK Gene and Protein Sequence

AAA AAA AAA GAG AAG GTG AAG AAG GGC AGC GAG TGT	36
Lys Lys Lys Glu Lys Val Lys Lys Gly Ser Glu Cys	
1 5 10	
TCG GAG TGG ACC TGG GGG CCC TGC ACC CCC AGC AGC	72
Ser Glu Trp Pro Trp Gly Pro Cys Thr Pro Ser Ser	
15 20	
AAG GAC TGC GGC ATG GGC TTC CGC GAG GGT ACC TGT	108
Lys Asp Cys Gly Met Gly Phe Arg Glu Gly Thr Cys	
25 30 35	
GGG GCC CAG ACC CAG CGC GTC CAT TGC AAG GTG CCC	144
Gly Arg Gln Thr Gln Arg Val His Cys Lys Val Pro	
40 45	
TGC AAC TGG AAG AAG GAA TTT GGA GCC GAC TGC AAA	180
Cys Asn Trp Lys Lys Glu Phe Gly Ala Asp Cys Lys	
50 55 60	
TAC AAG TTT GAG AGC TGG GGG GCG TGT GAT GGG AGC	216
Tyr Lys Phe Glu Ser Trp Gly Ala Cys Asp Gly Ser	
65 70	
ACT GGC ACC AAA GCC CGC CAA GGG ACC CTG AAG AAG	252
Thr Gly Thr Lys Ala Arg Gln Gly Thr Leu Lys Lys	
75 80	
GCG CGG TAC ACT GCC CAG TGC CAG GAG ACC ATC CGC	288
Ala Arg Tyr Thr Ala Gln Cys Gln Glu Thr Ile Arg	
85 90 95	
GTG ACT AAG CCC TGC ACC TCC AAG ACC AAG TCA AAG	324
Val Thr Lys Pro Cys Thr Ser Lys Thr Lys Ser Lys	
100 105	
ACC AAA GCC AAG AAA GGA AAA GGA AAG GAC	354
Thr Lys Ala Lys Lys Gly Lys Gly Lys Asp	
110 115 118	

Sequence ID No.: 3

Sequence Type: Nucleic Acid and Amino Acid

Sequence Length: 411 Base Pairs 136 Amino Acids

Strandedness: Single

Topology: Linear

Original Source Organism: Human

Properties: Human HBNF Gene and Protein Sequence

GGG AAG AAA GAG AAA CCA GAA AAA AAA GTG AAG AAG	36
Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys	
1 5 10	
TCT GAC TGT GGA GAA TGG CAG TGG AGT GTG TGT GTG	72
Ser Asp Cys Gly Glu Trp Gln Trp Ser Val Cys Val	
15 20	
CCC ACC AGT GGA GAC TGT GGG CTG GGC ACA CGG GAG	108
Pro Thr Ser Gly Asp Cys Gly Leu Gly Thr Arg Glu	
25 30 35	
GGC ACT CGG ACT GGA GCT GAG TGC AAG CAA ACC ATG	144
Gly Thr Arg Thr Gly Ala Glu Cys Lys Gln Thr Met	
40 45	
AAG ACC CAG AGA TGT AAG ATC CCC TGC AAC TGG AAG	180
Lys Thr Gln Arg Cys Lys Ile Pro Cys Asn Trp Lys	
50 55 60	
AAG CAA TTT GGC GCG GAG TGC AAA TAC CAG TTC CAG	216
Lys Gln Phe Gly Ala Glu Cys Lys Tyr Trp Phe Trp	
65 70	
GCC TGG GGA GAA TGT GAC CTG AAC ACA GCC CTG AAG	252
Ala Trp Gly Glu Cys Asp Leu Asn Thr Ala Leu Lys	
75 80	
ACC AGA ACT GGA AGT CTG AAG CGA GCC CTG CAC AAT	288
Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn	
85 90 95	
GCC GAA TGC CAG AAG ACT GTC ACC ATC TCC AAG CCC	324
Ala Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro	
100 105	
TGT GGC AAA CTG ACC AAG CCC AAA CCT CAA GCA GAA	360
Cys Gly Lys Leu Thr Lys Pro Lys Pro Gln Ala Glu	
110 115 120	

TCT AAG AAG AAG AAA AAG GAA GGC AAG AAA CAG GAG 396
Ser Lys Lys Lys Lys Lys Glu Gly Lys Lys Gln Glu
125 130

AAG ATG CTG GAT TAA 411
Lys Met Leu Asp Iaa
135 136

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. A purified and isolated DNA having the MK sequence depicted in Figure 1 encoding a human MK protein, or a portion thereof, which encodes a biologically active MK protein.
2. A DNA which is hybridizable with the MK sequence depicted in Figure 1 under standard high stringency conditions.
3. A method for production of pure human MK protein or a portion thereof which comprises transforming a host cell with the DNA of Claim 1 and culturing the host cell under conditions which permit expression of the DNA by the host cell.
4. An expression vector comprising the DNA of Claim 1.
5. A transgenic cell comprising the DNA of Claim 1.
6. The cell of Claim 5 which is deposited with the American Type Culture Collection as ATCC 68384.
7. A purified isolated MK protein having a sequence depicted in Figure 1 and homologues or fragments thereof which retain MK biological activity.
8. A therapeutic composition comprising an effective amount of the MK protein of Claim 7 in combination with a pharmaceutically acceptable carrier.
9. A method of maintaining or promoting growth of nerve cells in vitro which comprises culturing the cells in the presence of an effective amount of the protein of Claim 7.
10. A method for inducing differentiation of undifferentiated cells which comprises applying to the cells an effective amount of the protein of Claim 7.
11. Use of the cells of Claim 5 for preparing a composition for repairing or treating damaged nerve cells in vivo which comprises an effective amount of compatible transgenic cells capable of expressing an MK protein.

Claims for the following Contracting States : ES, GR

1. A method for production of pure human MK protein or a portion thereof which comprises transforming a host cell with a purified and isolated DNA having the MK sequence depicted in Figure 1 encoding a human MK protein, or a portion thereof, which encodes a biologically active MK protein, and culturing the host cell under conditions which permit expression of the DNA by the host cell.
2. A method according to claim 1, wherein said DNA is hybridizable with the MK sequence depicted in Figure 1 under standard high stringency conditions.
3. A method according to claim 1, wherein the protein obtainable comprises the sequence depicted in Figure 1 and

homologues or fragments thereof which retain MK biological activity.

4. A method of maintaining or promoting growth of nerve cells in vitro which comprises culturing the cells in the presence of an effective amount of a protein obtainable according to the process of any of claims 1 to 3.
5. A method for inducing differentiation of undifferentiated cells which comprises applying to the cells an effective amount of a protein obtainable according to the process of any of claims 1 to 3.
6. An expression vector comprising a purified and isolated DNA having the MK sequence depicted in Figure 1 encoding a human MK protein, or a portion thereof, which encodes a biologically active MK protein.
7. A transgenic cell comprising a purified and isolated DNA having the MK sequence depicted in Figure 1 encoding a human MK protein, or a portion thereof, which encodes a biologically active MK protein.
8. A cell according to claim 7, which is deposited with the American Type Culture Collection as ATCC 68384.
9. Use of the cells of claim 7 for preparing a composition for repairing or treating damaged nerve cells in vivo which comprises an effective amount of compatible transgenic cells capable of expressing an MK protein.
10. A process for producing a therapeutic composition which comprises the mixture of an effective amount of a protein obtainable according to the process of any of claims 1 to 3 with a pharmaceutically acceptable carrier.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Gereinigte und isolierte DNA mit der in Figur 1 dargestellten MK-Sequenz, die für ein menschliches MK-Protein kodiert, oder ein Teil derselben, der für ein biologisch aktives MK-Protein kodiert.
2. DNA, die mit der in Figur 1 dargestellten MK-Sequenz unter hochstringenten Standard-Bedingungen hybridisierbar ist.
3. Verfahren zur Herstellung von reinem menschlichem MK-Protein oder einem Teil desselben, umfassend das Transformieren einer Wirtszelle mit der DNA nach Anspruch 1 und das Kultivieren der Wirtszelle unter Bedingungen, die die Expression der DNA durch die Wirtszelle gestatten.
4. Expressionsvektor, der die DNA nach Anspruch 1 umfaßt.
5. Transgene Zelle, die die DNA nach Anspruch 1 umfaßt.
6. Zelle nach Anspruch 5, die bei der American Type Culture Collection als ATCC 68384 hinterlegt ist.
7. Gereinigtes, isoliertes MK-Protein mit einer in Figur 1 dargestellten Sequenz und Homologe oder Fragmente desselben, die die biologische MK-Aktivität beibehalten.
8. Therapeutische Zusammensetzung, die eine wirksame Menge des MK-Proteins nach Anspruch 7 in Kombination mit einem pharmazeutisch annehmbaren Träger umfaßt.
9. Verfahren zur Beibehaltung oder Förderung des Wachstums von Nervenzellen in vitro, umfassend das Kultivieren der Zellen in Anwesenheit einer wirksamen Menge des Proteins nach Anspruch 7.
10. Verfahren zur Induzierung einer Differenzierung von undifferenzierten Zellen, umfassend das Versetzen der Zellen mit einer wirksamen Menge des Proteins nach Anspruch 7.
11. Verwendung der Zellen nach Anspruch 5 zur Herstellung einer Zusammensetzung zur Wiederherstellung oder Behandlung von beschädigten Nervenzellen in vivo, welche eine wirksame Menge an kompatiblen transgenen Zel-

len umfaßt, die ein MK-Protein exprimieren können.

Patentansprüche für folgende Vertragsstaaten : ES, GR

- 5 1. Verfahren zur Herstellung von reinem menschlichem MK-Protein oder einem Teil desselben, umfassend das Transformieren einer Wirtszelle mit einer gereinigten und isolierten DNA mit der in Figur 1 dargestellten MK-Sequenz, die für ein menschliches MK-Protein kodiert, oder einem Teil derselben, der für ein biologisch aktives MK-Protein kodiert, und das Kultivieren der Wirtszelle unter Bedingungen, die die Expression der DNA durch die Wirtszelle gestatten.
- 10 2. Verfahren nach Anspruch 1, bei dem die DNA mit der in Figur 1 dargestellten MK-Sequenz unter hochstringenten Standard-Bedingungen hybridisierbar ist.
- 15 3. Verfahren nach Anspruch 1, bei dem das erhaltliche Protein die in Figur 1 dargestellte Sequenz und Homologe oder Fragmente derselben umfaßt, die eine biologische MK-Aktivität beibehalten.
- 20 4. Verfahren zur Beibehaltung oder Förderung des Wachstums von Nervenzellen in vitro, umfassend das Kultivieren der Zellen in der Anwesenheit einer wirksamen Menge eines Proteins, das durch das Verfahren nach irgendeinem der Ansprüche 1 bis 3 erhältlich ist.
- 25 5. Verfahren zur Induzierung der Differenzierung von undifferenzierten Zellen, umfassend das Versetzen der Zellen mit einer wirksamen Menge eines Proteins, das nach dem Verfahren nach irgendeinem der Ansprüche 1 bis 3 erhältlich ist.
- 30 6. Expressionsvektor, umfassend eine gereinigte und isolierte DNA mit der in Figur 1 dargestellten MK-Sequenz, die für ein menschliches MK-Protein kodiert, oder einen Teil derselben, der für ein biologisch aktives MK-Protein kodiert.
7. Transgene Zelle, umfassend eine gereinigte und isolierte DNA mit der in Figur 1 dargestellten MK-Sequenz, die für ein menschliches MK-Protein kodiert, oder einen Teil derselben, der für ein biologisch aktives MK-Protein kodiert.
8. Zelle nach Anspruch 7, die bei der American Type Culture Collection als ATCC 68384 hinterlegt ist.
- 35 9. Verwendung der Zellen nach Anspruch 7 zur Herstellung einer Zusammensetzung zur Wiederherstellung oder Behandlung von beschädigten Nervenzellen in vivo, welche eine wirksame Menge an kompatiblen transgenen Zellen umfaßt, die ein MK-Protein exprimieren können.
- 40 10. Verfahren zur Herstellung einer therapeutischen Zusammensetzung, umfassend das Mischen einer wirksamen Menge eines nach dem Verfahren von irgendeinem der Ansprüche 1 bis 3 erhältlichen Proteins mit einem pharmazeutisch annehmbaren Träger.

Revendications

45

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

- 50 1. ADN purifié et isolé, ayant la séquence de MK décrite dans la figure 1, codant pour une protéine MK humaine, ou une portion de celle-ci, qui code pour une protéine MK biologiquement active.
2. ADN pouvant être hybridé à la séquence MK décrite dans la Figure 1 dans des conditions hautement stringentes standard.
- 55 3. Procédé de production de protéine MK humaine pure ou d'une portion de celle-ci, qui comprend la transformation d'une cellule hôte par l'ADN de la revendication 1 et la culture de la cellule hôte dans des conditions qui permettent l'expression de l'ADN par la cellule hôte.
4. Vecteur d'expression comprenant l'ADN de la revendication 1.

5. Cellule transgénique comprenant l'ADN de la revendication 1.
6. Cellule de la revendication 5, qui est déposée à l'American Type Culture Collection sous le numéro d'accèsion ATCC 68384.
7. Protéine MK isolée purifiée ayant une séquence décrite dans la figure 1, et homologues ou fragments de celle-ci qui conservent l'activité biologique de MK.
8. Composition thérapeutique comprenant une quantité efficace de la protéine MK de la revendication 7 en combinaison avec un véhicule acceptable du point de vue pharmaceutique.
9. Procédé d'entretien ou d'activation de la croissance de cellules nerveuses *in vitro* qui comprend la culture des cellules en présence d'une quantité efficace de la protéine selon la revendication 7.
10. Procédé d'induction de la différenciation de cellules indifférenciées qui comprend l'application aux cellules d'une quantité efficace de la protéine de la revendication 7.
11. Utilisation des cellules de la revendication 5 pour la préparation d'une composition pour l'entretien ou le traitement des cellules nerveuses endommagées *in vivo* qui comprend une quantité efficace de cellules transgéniques compatibles capables d'exprimer une protéine MK.

Revendications pour les Etats contractants suivants : ES, GR

1. Procédé de production de protéine MK humaine pure ou d'une portion de celle-ci, qui comprend la transformation d'une cellule hôte par un ADN purifié et isolé, ayant la séquence de MK décrite dans la figure 1, codant pour une protéine MK humaine, ou une portion de celle-ci, qui code pour une protéine MK biologiquement active, et la culture de la cellule hôte dans des conditions qui permettent l'expression de l'ADN par la cellule hôte.
2. Procédé selon la revendication 1, dans lequel ledit ADN peut être hybridé à la séquence MK décrite dans la figure 1 dans des conditions hautement stringentes standards.
3. Procédé selon la revendication 1, dans lequel la protéine qu'il est possible d'obtenir comprend la séquence décrite dans la figure 1 et des homologues ou fragments de celle-ci qui conservent l'activité biologique de MK.
4. Procédé d'entretien ou d'activation de la croissance de cellules nerveuses *in vitro* qui comprend la culture des cellules en présence d'une quantité efficace d'une protéine qu'il est possible d'obtenir selon le procédé de l'une quelconque des revendications 1 à 3.
5. Procédé d'induction de la différenciation de cellules indifférenciées, qui comprend l'application aux cellules d'une quantité efficace d'une protéine qu'il est possible d'obtenir selon le procédé de l'une quelconque des revendications 1 à 3.
6. Vecteur d'expression comprenant un ADN purifié et isolé, ayant la séquence de MK décrite dans la figure 1, codant pour une protéine MK humaine, ou une portion de celle-ci, qui code pour une protéine MK biologiquement active.
7. Cellule transgénique comprenant un ADN purifié et isolé, ayant la séquence de MK décrite dans la figure 1, codant pour une protéine MK humaine, ou une portion de celle-ci, qui code pour une protéine MK biologiquement active.
8. Cellule selon la revendication 7, qui est déposée à l'American Type Culture Collection sous le numéro d'accèsion ATCC 68384.
9. Utilisation des cellules selon la revendication 7, pour la préparation d'une composition pour l'entretien ou le traitement des cellules nerveuses endommagées *in vivo*, qui comprend une quantité efficace de cellules transgéniques compatibles capables d'exprimer une protéine MK.
10. Procédé de production d'une composition thérapeutique comprenant le mélange d'une quantité efficace d'une protéine qu'il est possible d'obtenir selon le procédé de l'une quelconque des revendications 1 à 3 avec un véhicule

acceptable du point de vue pharmaceutique.

5

10

15

20

25

30

35

40

45

50

55

FIG. 1

	1	G	K	K	E	K	P	E	K	K	V	K	K	S	D	C	G	E	
HBNF	1	GGG	AAG	AAA	GAG	AAA	CCA	GAA	AAA	AAA	GTG	AAG	AAG	TCT	GAC	TGT	GGA	GAA	
		***	***	**	**		*	**		*		*	*		**	**	*	**	
MK	1	AAA	AAG	AAA	GAT	AAG	GTG	AAG	AAG	GGC	GGC	CCG	GGG	AGC	GAG	TGC	GCT	GAG	
	1	K	K	K	D	K	V	K	K	G	G	P	G	S	E	C	A	E	
	18	W	Q	W	S	V	C	V	P	T	S	G	D	C	G	L	G	T	
HBNF	52	TGG	CAG	TGG	AGT	GTG	TGT	GTG	CCC	ACC	AGT	GGA	GAC	TGT	GGG	CTG	GGC	ACA	
		***		***	*		**		***	*	*	**		**	**	**	**	**	
MK	52	TGG	GCC	TGG	GGG	CCC	TGC	ACC	CCC	AGC	AGC	AAG	GAT	TGC	GGC	GTG	GGT	TTC	
	18	W	A	W	G	P	C	T	P	S	S	K	D	C	G	V	G	F	
	35	R	E	G	T	R	T	G	A	E	C	K	Q	T	M	K	T	Q	
HBNF	103	CGG	GAG	GGC	ACT	CGG	ACT	GGA	GCT	GAG	TGC	AAG	CAA	ACC	ATG	AAG	ACC	CAG	
		**	***	***	**						***	*			*	**	*		
MK	103	CGC	GAG	GGC	ACC	-	-	-	-	-	TGC	GGG	GCC	CAG	ACC	CAG	CGC	ATC	
	35	R	E	G	T	-	-	-	-	-	C	G	A	Q	T	Q	R	I	
	52	R	C	K	I	P	C	N	W	K	K	Q	F	G	A	E	C	K	
HBNF	154	AGA	TGT	AAG	ATC	CCC	TGC	AAC	TGG	AAG	AAG	CAA	TTT	GGC	GCG	GAG	TGC	AAA	
		*	**	**	*	*	***	***	***	***	***	***	*	***	**	**	**	***	**
MK	139	CGG	TGC	AGG	GTG	CCC	TGC	AAC	TGG	AAG	AAG	GAG	TTT	GGA	GCC	GAC	TGC	AAG	
	47	R	C	R	V	P	C	N	W	K	K	E	F	G	A	D	C	K	

FIG. 2

69 Y Q F Q A W G E C D L N T A L K T
 HBNF 205 TAC CAG TTC CAG GCC TGG GGA GAA TGT GAC CTG AAC ACA GCC CTG AAG ACC
 *** ** ** ** * *** ** * *** ** * * *** * * ** *
 MK 190 TAC AAG TTT GAG AAC TGG GGT GCG TGT GAT GGG GGC ACA GGC ACC AAA GTC
 64 Y K F E N W G A C D G G T G T K V

 86 R T G S L K R A L H N A E C Q K T
 HBNF 256 AGA ACT GGA AGT CTG AAG CGA GCC CTG CAC AAT GCC GAA TGC CAG AAG ACT
 * ** * *** *** ** * ** *** ** * *** *** ** **
 MK 241 CGC CAA GGC ACC CTG AAG AAG GCG CGC TAC AAT GCT CAG TGC CAG GAG ACC
 81 R Q G T L K K A R Y N A Q C Q E T

 103 V T I S K P C G K L T K P K P Q A
 HBNF 307 GTC ACC ATC TCC AAG CCC TGT GGC AAA CTG ACC AAG CCC AAA CCT CAA GCA
 ** * ** ** *** *** ** * * *** ** * ** * ** **
 MK 292 ATC CGC GTC ACC AAG CCC TGC ACC CCC AAG ACC AAA GCA AAG GCC AAA GCC
 98 I R V T K P C T P K T K A K A K A

 120 E S K K K K K E G K K Q E K M L D
 HBNF 358 GAA TCT AAG AAG AAG AAA AAG GAA GGC AAG AAA CAG GAG AAG ATG CTG GAT
 * * *** ** * *
 MK 343 AAG AAA GGG AAG GGA AAG GAC TAG
 115 K K G K G K D *

 137 *
 HBNF 409 TAA

FIG. 2 (cont.)

	1	K	K	K	E	K	V	K	K	G	-	-	-	S	E	C	S	E
MOU	1	AAA	AAA	AAA	GAG	AAG	GTG	AAG	AAG	GGC	-	-	-	AGC	GAG	TGT	TCG	GAG
HUM	1	AAA	AAG	AAA	GAT	AAG	GTG	AAG	AAG	GGC	GGC	CCG	GGG	AGC	GAG	TGC	GCT	GAG
	1	K	K	K	D	K	V	K	K	G	G	P	G	S	E	C	A	E
	15	V	P	V	G	P	C	T	P	S	S	K	D	C	G	H	G	F
MOU	43	TGG	ACC	TGG	GGG	CCC	TGC	ACC	CCC	AGC	AGC	AAG	GAC	TGC	GGC	ATG	GGC	TTC
HUM	52	TGG	GGC	TGG	GGG	CCC	TGC	ACC	CCC	AGC	AGC	AAG	GAT	TGC	GGC	GTG	GGT	TTC
	18	V	A	V	G	P	C	T	P	S	S	K	D	C	G	V	G	F
	32	R	E	G	T	C	G	A	Q	T	Q	R	V	H	C	K	V	P
MOU	94	CGC	GAG	GGT	ACC	TGT	GGG	GCC	CAG	ACC	CAG	CGC	GTC	CAT	TGC	AAG	GTG	CCC
HUM	103	CGC	GAG	GGC	ACC	TGC	GGG	GCC	CAG	ACC	CAG	CGC	ATC	CGG	TGC	AGG	GTG	CCC
	35	R	E	G	T	C	G	A	Q	T	Q	R	I	R	C	R	V	P
	49	C	N	V	K	K	E	F	G	A	D	C	K	Y	K	F	E	S
MOU	145	TGC	AAC	TGG	AAG	AAG	GAA	TTT	GGA	GCC	GAC	TGC	AAA	TAC	AAG	TTT	GAG	AGC
HUM	154	TGC	AAC	TGG	AAG	AAG	GAG	TTT	GGA	GCC	GAC	TGC	AAG	TAC	AAG	TTT	GAG	AAC
	52	C	N	V	K	K	E	F	G	A	D	C	K	Y	K	F	E	N
	66	V	G	A	C	D	G	S	T	G	T	K	A	R	Q	G	T	L
MOU	196	TGG	GGG	GCG	TGT	GAT	GGG	AGC	ACT	GGC	ACC	AAA	GCC	CGC	CAA	GGG	ACC	CTG
HUM	205	TGG	GGT	GCG	TGT	GAT	GGG	GGC	ACA	GGC	ACC	AAA	GTC	CGC	CAA	GGC	ACC	CTG
	69	V	G	A	C	D	G	G	T	G	T	K	V	R	Q	G	T	L
	83	K	K	A	R	Y	T	A	Q	C	Q	E	T	I	R	V	T	K
MOU	247	AAG	AAG	GCG	CGG	TAC	ACT	GCC	CAG	TGC	CAG	GAG	ACC	ATC	CGC	GTG	ACT	AAG
HUM	256	AAG	AAG	GCG	CGC	TAC	AAT	GCT	CAG	TGC	CAG	GAG	ACC	ATC	CGC	GTC	ACC	AAG
	86	K	K	A	R	Y	N	A	Q	C	Q	E	T	I	R	V	T	K
	100	P	C	T	S	K	T	K	S	K	T	K	A	K	K	G	K	G
MOU	298	CCC	TGC	ACC	TCC	AAG	ACC	AAG	TCA	AAG	ACC	AAA	GCC	AAG	AAA	GGA	AAA	GGA
HUM	307	CCC	TGC	ACC	CCC	AAG	ACC	AAA	GCA	AAG	GCC	AAA	GCC	AAG	AAA	GGG	AAG	GGA
	103	P	C	T	P	K	T	K	A	K	A	K	A	K	K	G	K	G
	117	K	D															
MOU	349	AAG	GAC	TAG														
HUM	358	AAG	GAC	TAG														
	120	K	D															

FIG. 3




FIG. 4




FIG. 5A



FIG. 5B



FIG. 5C




FIG. 5D




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)